Aspreva raises revenue guidance

Aspreva (TSX:ASV; ASPV) rose C$2 (13%) to C$17 on Friday after increasing its 2005 revenue guidance to US$65-US$70 million from US$55-US$60 million. The increase follows an audit of second quarter sales of Roche's CellCept mycophenolate mofetil, for which ASV receives royalties on non-transplant indications. The audit, which happens every quarter under the companies' deal, showed that second quarter non-transplant sales were higher than previously estimated by the partners. ASV will book a royalty adjustment in its fourth quarter results. ...